News

Diabetes expert accuses drug company of “intimidation”

BMJ 2007; 335 doi: 10.1136/bmj.39409.458611.DB (Published 29 November 2007)
Cite this as: BMJ 2007;335:1113.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bob Burton
  1. Canberra

    The former chairman of research and development at GlaxoSmithKline, Tadataka Yamada, has been asked by a US Senate committee to explain his role in what it describes as the “intimidation” of John Buse, a professor of medicine at the University of North Carolina.

    In 1999 Dr Buse raised questions about the cardiovascular safety of the diabetes drug rosiglitazone, which is marketed as Avandia (BMJ 2007;334:1237 doi: 10.1136/bmj.39244.394456.DB). He was speaking at a symposium organised by the American Diabetes Association.

    A report by the Senate Finance Committee staff has shown that a company official emailed Dr Yamada proposing that a “firm letter” be written to Dr Buse containing a warning that “the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular